[Surfactant and respiratory distress syndrome].
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000551:Ambroxol / Q000627:therapeutic use; D000653:Amniotic Fluid / Q000032:analysis; D000818:Animals; D003907:Dexamethasone / Q000627:therapeutic use; D005938:Glucocorticoids / Q000009:adverse effects; D006801:Humans; D006819:Hyaline Membrane Disease / Q000517:prevention & control; D007231:Infant, Newborn; D007234:Infant, Premature; D008168:Lung / Q000254:growth & development; D010713:Phosphatidylcholines / Q000032:analysis; D011296:Prenatal Diagnosis; D011650:Pulmonary Alveoli / Q000378:metabolism; D011663:Pulmonary Surfactants; D011817:Rabbits; D051381:Rats; D012127:Respiratory Distress Syndrome, Newborn / Q000503:physiopathology*; D013109:Sphingomyelins / Q000032:analysis
D000318:Adrenergic beta-Agonists; D005938:Glucocorticoids; D010713:Phosphatidylcholines; D011663:Pulmonary Surfactants; D013109:Sphingomyelins; D000551:Ambroxol; D003907:Dexamethasone
Surfactant und Respiratory Distress Syndrome.